About this Research Topic
Personalized medicine aims to move away from a “one size fits all” approach to the treatment of various diseases in patients in recognition that there exists variation between individuals or specific populations. The current paradigm for personalizing disease treatment relies on molecular profiling approaches to identify biomarkers that can stratify patients. However, there are some caveats with a biomarker-based approach to personalized medicine – biomarkers are not available for all disease indications and developing new biomarkers that are targetable can take a very long time.
Based on the tenet that the best prediction of treatment response is treatment response itself, engineered tissue models generated using patient-derived cells can be used as patient surrogates to directly test various therapies on. This would require advancement in the design of tissue engineering strategies to specifically support and maintain patient-derived cells/tissues in a platform that is scalable for drug testing applications. New phenotypic assays compatible with the engineered tissue platform must also be developed to functionally measure differential responses to various therapeutic modality. Finally, systematic validation studies correlating in vitro response results to that of in vivo or clinical testing would be critical to determine the predictive value of the engineered tissue models.
We welcome the following themes:
• Biomaterials, biofabrication and cell culture technologies tailored for the maintenance of patient-derived cells (i.e. primary and iPSC-derived cells) and tissues
• Engineered artificial microenvironments to mimic tissue microenvironment
• Drug testing platform and studies using patient-derived models
• In vitro-in vivo/clinical validation studies
Keywords: phenomics, tissue models, bioengineering, personalized
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.